ГоловнаArchive of numbers2016Volume 24, issue 3 (88)Peculiarities of therapy of schizophrenia complicated using psychoactive substance
Title of the article Peculiarities of therapy of schizophrenia complicated using psychoactive substance
Authors Kramar Yuliia
In the section HELP TO PRACTICAL PHYSICIAN
Year 2016 Issue Volume 24, issue 3 (88) Pages 87-88
Type of article Scientific article Index UDK 616.895.8:02-036 Index BBK -
Abstract Patients with schizophrenia more often consume cannabinoids among psychoactive substances. According lite rature reviews was found eff ectiveness of risperidone, olanzapine and clozapine in this combination. Purpose of research is comparing effectiveness of olanzapine with risperidone. 120 patients were randomized in investigation. Mean time for reaching full reduction symptoms for risperidone was 14weeks and 16 weeks for olanzapine. Both olanzapine and risperidone show statistical proved eff ectiveness in treatment psychotic disorders. Olanzapine shows better result relation improvement negative symptoms, but despite the side eff ects, prescription this drug should considering risk and eff ectiveness.
Key words schizophrenia, cannabinoids, therapy comorbidity disorders
Access to full text version of the article pdf download
Bibliography 1. Comorbid substance use and age at onset of schizophrenia / T. R. Barnes, S. H. Mutsatsa, S. B. Hutton et al. // British Journal of Psychiatry. — 2006. — № 188 (1). — Р. 237—242. 2. Substance use in a population-based clinic sample of people with first-episode psychosis / J. H. Barnett, U. Werners, S. M. Secher et al. // Ibid. — 2007. — № 190 (1) — P. 515—520. 3. Substance misuse in first-episode psychosis: 15-month prospective follow-up study / D. Wade, S. Harrigan, J. Edward, P. M. Burgess et al. // Ibid. — 2006. — № 189 (2). — P. 229—234. 4. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial / L. J. van Nimwegen, L. de Haan, N. J. van Beveren et al. // Canadian Journal of Psychiatry. — 2008. — № 53 (1). — P. 400—405. 5. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone / A. I. Green, E. S. Burgess, R. Dawson et al. // Schizophrenia Research. — 2003. — № 60 (1). — P. 81—85. 6. The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency / S. Potvin, E. Stip, J. Y. Roy et al. // Canadian Journal of Psychiatry. — 2004. — № 49 (1). — P. 711. 7. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia / R. E. Drake, H. Xie, G. J. McHugo et al. // Schizophrenia Bulletin. — 2000. — № 26. — P. 441—449. 8. Akerele E. Comparison of olanzapine to risperidone in substance- abusing individuals with schizophrenia / E. Akerele, F. R. Levin // American Journal of Addiction. — 2007. — № 16. — Р. 260—268. 9. McEvoy J. P. Smoking and therapeutic response to clozapine in patients with schizophrenia / J. P. McEvoy, O. Freudenreich, W. H. Wilson // Biological Psychiatry. — 1999. — № 46. — P. 125—129. 10. Randomized comparison of olanzapine versus risperidone for the treatment of first-epi sode schizophrenia: 4-month outcomes / D. G. Robinson, M. G. Woerner, B. Napolitano et al. // American Journal of Psychiatry. — 2006. — № 163. — P. 2096—2102. 11. Clozapine use and relapses of su bstance use disorder among patients with co-occurring schizophrenia and substance use disorders / M. F. Brunette, R. E. Drake, H. Xie et al. // Schizophrenia Bulletin. — 2006. — № 32. — P. 3 7—643.